Edmund Harrigan
Director/Board Member chez ACADIA PHARMACEUTICALS INC.
Fortune : 1 M $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Stephen Davis | M | 63 | 10 ans | |
Julian Baker | M | 57 | 23 ans | |
Herve Hoppenot | M | 64 | 10 ans | |
Stéphane Thiroloix | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 6 ans |
Clay Thorp | M | 55 | 22 ans | |
Jason Brown | M | 37 | 6 ans | |
Jennifer J. Rhodes | F | 53 | 7 ans | |
Jonathan Mow | M | 59 | 12 ans | |
Mark Schneyer | M | 50 | 13 ans | |
Stephen Biggar | M | 53 | 11 ans | |
Nancy Hutson | M | 74 | 32 ans | |
James Daly | M | 63 | 8 ans | |
Susanne Antonie Schaffert | M | 57 | 2 ans | |
Susan Arnold | M | 49 | 14 ans | |
Joseph Echevarria | M | 66 | 9 ans | |
Albert Kildani | M | - | 1 ans | |
Alex Sapir | M | 57 | 4 ans | |
Katherine High | M | 72 | 4 ans | |
Bob Mischler | M | - | 9 ans | |
Scott A. Byrd | M | 54 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
Kristopher Hanson | M | 52 | 5 ans | |
Elizabeth Garofalo | M | 66 | 4 ans | |
Lawrence Perkins | M | 47 | 2 ans | |
Brendan Teehan | M | 56 | 6 ans | |
Julie Fisher | F | - | 6 ans | |
Thomas Tray | M | 46 | 19 ans | |
Pablo Cagnoni | M | 60 | 1 ans | |
Sheila Denton | F | 58 | 1 ans | |
Katherine Bishop | M | 58 | 3 ans | |
Jacqualyn Fouse | M | 62 | 7 ans | |
Sally Susman | F | 62 | 17 ans | |
Jean-Jacques Bienaimé | M | 70 | 9 ans | |
Shantanu Narayen | M | 60 | 11 ans | |
Otis Brawley | M | 64 | 3 ans | |
Don Soland | M | 65 | 9 ans | |
Helen H. Hobbs | M | 71 | 13 ans | |
Laura Brege | F | 66 | 16 ans | |
Olivier Jean Bohuon | M | 65 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 6 ans |
William Humphries | M | 57 | 3 ans | |
Jim Smith | M | 64 | 10 ans | |
Suzanne Johnson | F | 66 | 17 ans | |
Paul Clancy | M | 62 | 9 ans | |
Richard van den Broek | M | 57 | 5 ans | |
Thibaut Roulon | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
Benir Ruano | M | - | 2 ans | |
Denise Brashear | F | - | 2 ans | |
Kevin Oliver | M | - | 1 ans | |
Sanjeev Pathak | M | - | 3 ans | |
Holly Valdiviez | F | - | 2 ans | |
Kimberly Manhard | F | 64 | - | |
Barbara Dalton | M | 69 | 17 ans | |
Adora Ndu | M | 43 | 2 ans | |
Keith Mikkelson | M | - | 22 ans | |
Mikael Dolsten | M | 65 | 15 ans | |
James Kihara | M | - | 4 ans | |
Benjamin J. Strain | M | - | 1 ans | |
Parag V. Meswani | M | - | 2 ans | |
Ponni Subbiah | M | - | 5 ans | |
Claire Poulard | F | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
Hugues le Bret | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 5 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 94 | 94,00% |
France | 6 | 6,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Edmund Harrigan
- Réseau Personnel